What 11 Analyst Ratings Have To Say About Immunovant
Portfolio Pulse from Benzinga Insights
Immunovant (NASDAQ:IMVT) has received 11 analyst ratings in the last quarter, with 9 being bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target for the company is $28.27, with a high of $34.00 and a low of $4.00. The average price target has increased by 6.2% over the past month.
August 16, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant has received mostly bullish analyst ratings in the last quarter, which could positively impact its stock price. The average 12-month price target has also increased over the past month.
Analyst ratings can significantly influence a company's stock price. In Immunovant's case, the majority of the ratings are bullish, indicating a positive outlook for the company. Additionally, the increase in the average price target over the past month suggests that analysts are becoming more optimistic about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100